School of Medicine
Showing 241-260 of 493 Results
-
Ruben Y. Luo
Assistant Professor of Pathology
Current Research and Scholarly InterestsApply top-down mass spectrometry and label-free immunoassay to the study and utilization of biomarker proteoforms in clinical diagnosis.
-
Xuchao Lyu
Postdoctoral Scholar, Pathology
BioDr. XuchaoLyu (Lv) reveived his bachelor's degree in biology and chemistry from Jilin University, China in 2011. He completed his Ph.D. in metabolism disease at Tsinghua University in 2019. He worked with Peng Li to study the mechanism of lipid droplet growth. He uncovered the unique lipid-permeable condensate that allows lipid transfer which is formed through 2D phase separation on the phospholipid membrane. Xuchao is currently a postdoc in Jonathan Long's lab at Stanford University. He is studying the secreted factors from various tissues during exercise. Outside of the lab, he enjoys eating and cooking.
-
Morgan Mann
Postdoctoral Scholar, Pathology
BioMorgan W. Mann, PhD, is a postdoctoral researcher at Stanford University and clinical chemistry DABCC fellow at the University of California – San Francisco (UCSF). His personal and professional interests involve the development of novel clinical assays to streamline medical diagnostics and address emerging challenges to our healthcare systems. Prior to his joint positions at Stanford and UCSF, Morgan earned his PhD in Cellular and Molecular Pathology at the University of Wisconsin – Madison, where he applied mass spectrometry-based proteomics to study innate inflammation signaling pathways and viral protein structure in the context of airway infection. He received dual bachelor’s degrees in Biochemistry and Mathematics from the University of Oklahoma.
-
Magdalena Matusiak
Instructor, Pathology
Current Research and Scholarly InterestsMy research focuses on revealing clinically relevant prognostic markers associated with myeloid cell biology in solid malignancies. I currently. lead two main projects: first, using single-cell RNA Sequencing and bulk tissue genomics to discover tumor-associated macrophage (TAM) diversity and establish their prognostic and predictive markers, second: using multiplex tissue imaging (MIBI) to unravel prognostic markers of spatial heterogeneity in the colon cancer.
